Vascular disorders of the liver

Hepatology

Volumn 49, Issue 5, 2009, Pages 1729-1764

  DeLeve, Laurie D ^a   Valla, Dominique Charles ^b,d   Garcia Tsao, Guadalupe ^c  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b BEAUJON HOSPITAL   (France)

^c YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d Institut National de la Santé   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALKYLATING AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; AZATHIOPRINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUSULFAN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DACARBAZINE; DACTINOMYCIN; DEFIBROTIDE; FIBRINOLYTIC AGENT; FLUDARABINE; GEMTUZUMAB OZOGAMICIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; MELPHALAN; MERCAPTOPURINE; OXALIPLATIN; PENTOXIFYLLINE; PLACEBO; PROSTAGLANDIN E1; TIOGUANINE; TISSUE PLASMINOGEN ACTIVATOR; UNINDEXED DRUG; URETHAN; URSODEOXYCHOLIC ACID;

ACUTE DISEASE; ANGIOPLASTY; ARTERIOVENOUS MALFORMATION; ARTICLE; ARTIFICIAL EMBOLISM; BILE DUCT DISEASE; BUDD CHIARI SYNDROME; CARDIOVASCULAR DISEASE; CHILDHOOD DISEASE; CHOLESTASIS; CHRONIC DISEASE; CLINICAL TRIAL; CONGENITAL ARTERIOPORTAL MALFORMATION; CONGENITAL BLOOD VESSEL MALFORMATION; CONGENITAL PORTOSYSTEMIC SHUNT; DIAGNOSTIC IMAGING; DIET THERAPY; DOSE RESPONSE; DRUG DOSE SEQUENCE; DRUG MECHANISM; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOSCOPIC SCLEROTHERAPY; ENDOTHELIAL DYSFUNCTION; FEVER; GASTROINTESTINAL HEMORRHAGE; HISTOPATHOLOGY; HUMAN; INFECTION; INTESTINE INFARCTION; ISCHEMIA; JAUNDICE; LABORATORY DIAGNOSIS; LEUKOCYTOSIS; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER INJURY; LIVER ISCHEMIA; LIVER TRANSPLANTATION; LIVER VEIN OBSTRUCTION; LIVER VENOOCCLUSIVE DISEASE; MULTIPLE ORGAN FAILURE; NONHUMAN; PATHOGENESIS; PORTAL HYPERTENSION; PORTAL VEIN OBSTRUCTION; PORTAL VEIN THROMBOSIS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECANALIZATION; RECURRENT DISEASE; RENDU OSLER WEBER DISEASE; SHOCK; SPLENORENAL SHUNT; STENT; THROMBOCYTOPENIA; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; UNSPECIFIED SIDE EFFECT; VASCULAR DISEASE; WHOLE BODY RADIATION; CHEMICALLY INDUCED DISORDER; CHILD; PORTAL VEIN; VEIN THROMBOSIS;

BUDD-CHIARI SYNDROME; CHILD; HEPATIC VENO-OCCLUSIVE DISEASE; HUMANS; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; PORTAL VEIN; TELANGIECTASIA, HEREDITARY HEMORRHAGIC; VENOUS THROMBOSIS;

EID: 66149155797     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22772     Document Type: Article

References (368)

1. Eddy DM. A Manual for Assessing Health Practices and Designing Practice Guidelines. Philadelphia, PA: American College of Physicians; 1996: 1-126.
2. Position and policy statement: American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995;108: 925-926.
3. Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: A proposal from the conference on guideline standardization. Ann Intern Med 2003;139:493-498.
4. American Heart Association. Methodology Manual. http://www-.heart.org/ presenter.jhtml?identifier=3039683. Accessed December 2008.
5. Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: Prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006;12:2115-2119.
6. Arora NK, Lodha R, Gulati S, Gupta AK, Mathur P, Joshi MS, et al. Portal hypertension in north Indian children. Indian J Pediatr 1998;65: 585-591.
7. Condat B, Pessione F, Denninger MH, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: Increased recognition and frequent recanalization on anticoagulant therapy. HEPATOLOGY 2000;32:466-470.
8. Chamouard P, Pencreach E, Maloisel F, Grunebaum L, Ardizzone JF, Meyer A, et al. Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology 1999;116:144-148.
9. Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, et al. Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: Results of a case-control study. Blood 2000;96:2364-2368.
10. Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, et al. Risk factors for thrombophilia in extrahepatic portal vein obstruction. HEPATOLOGY 2005;41:603-608.
11. Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, et al. Cause of portal or hepatic venous thrombosis in adults: The role of multiple concurrent factors. HEPATOLOGY 2000;31:587-591.
12. Plemmons RM, Dooley DP, Longfield RN. Septic thrombophlebitis of the portal vein (pylephlebitis): Diagnosis and management in the modern era. Clin Infect Dis 1995;21:1114-1120.
13. Webb LJ, Sherlock S. The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med 1979;48:627-639.
14. Bhattacharyya M, Makharia G, Kannan M, Ahmed RP, Gupta PK, Saxena R. Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: A study from North India. Am J Clin Pathol 2004;121:844-847.
15. Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997;40: 798-800.
16. Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: A study from Western India. HEPATOLOGY 2001;34:666-670.
17. Ahuja V, Marwaha N, Chawla Y, Dilawari JB. Coagulation abnormalities in idiopathic portal venous thrombosis. J Gastroenterol Hepatol 1999; 14:1210-1211.
18. Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, Dandrea G, et al. High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis. Am J Gastroenterol 2001;96:146-149.
19. Egesel T, Buyukasik Y, Dundar SV, Gurgey A, Kirazli S, Bayraktar Y. The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. J Clin Gastroenterol 2000;30:66-71.
20. Fennerty A. Venous thromboembolic disease and cancer. Postgrad Med J 2006;82:642-648.
21. Aird WC. Sepsis and coagulation. Crit Care Clin 2005;21:417-431.
22. Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, et al. Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005;129:553-560.
23. Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, et al. Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988;94: 1063-1069.
24. Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, et al. The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5:55-61.
25. De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, et al. Prevalence of the JAK2(V617F) mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007;5:708-714.
26. Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, et al. The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases. Blood 2008;111: 4022-4029.
27. Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, et al. Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. HEPATOLOGY 2006;44: 1528-1534.
28. Fisher NC, Wilde JT, Roper J, Elias E. Deficiency of natural anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon? Gut 2000;46:534-539.
29. Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, et al. Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004;40:736-741.
30. Duchmann JC, Joly JP, Biny JP, Sevestre H, Capron JP. Portal thrombosis and liver cirrhosis. Value of ultrasound-guided puncture-biopsy of the thrombus. [in French] Gastroenterol Clin Biol 1995;19:581-586.
31. Tarantino L, Francica G, Sordelli I, Esposito F, Giorgio A, Sorrentino P, et al. Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: Color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdom Imaging 2006;31: 537-544.
32. Trum JW, Valla D, Cohen G, Degott C, Rueff B, Santoni P, et al. Bacteroides bacteremia of undetermined origin: Strong association with portal vein thrombosis and cryptogenic pylephlebitis. Eur J Gastroenterol Hepatol 1993;5:655-659.
33. Grendell JH, Ockner RK. Mesenteric venous thrombosis. Gastroenterology 1982;82:358-372.
34. Sheen CL, Lamparelli H, Milne A, Green I, Ramage JK. Clinical features, diagnosis and outcome of acute portal vein thrombosis. Q J Med 2000; 93:531-534.
35. Clavien PA. Diagnosis and management of mesenteric infarction. Br J Surg 1990;77:601-603.
36. Valla DC, Condat B. Portal vein thrombosis in adults: Pathophysiology, pathogenesis and management. J Hepatol 2000;32:865-871.
37. Kumar S, Sarr M, Kamath PS. Mesenteric venous thrombosis. N Engl J Med 2001;345:1683-1688.
38. Dourakis SP, Tsochatzis E, Alexopoulou A, Archimandritis AJ. Pylephlebitis complicating silent diverticulitis. Lancet 2006;368:422.
39. Haddad MC, Clark DC, Sharif HS, al Shahed M, Aideyan O, Sammak BM. MR, CT, and ultrasonography of splanchnic venous thrombosis. Gastrointest Radiol 1992;17:34-40.
40. Kreft B, Strunk H, Flacke S, Wolff M, Conrad R, Gieseke J, et al. Detection of thrombosis in the portal venous system: Comparison of contrast-enhanced MR angiography with intraarterial digital subtraction angiography. Radiology 2000;216:86-92.
41. Rahmouni A, Mathieu D, Golli M, Douek P, Anglade MC, Caillet H, et al. Value of CT and sonography in the conservative management of acute splenoportal and superior mesenteric venous thrombosis. Gastrointest Radiol 1992;17:135-140.
42. Tessler FN, Gehring BJ, Gomes AS, Perrella RR, Ragavendra N, Busuttil RW, et al. Diagnosis of portal vein thrombosis: Value of color Doppler imaging. AJR Am J Roentgenol 1991;157:293-296.
43. Wiersema MJ, Chak A, Kopecky KK, Wiersema LM. Duplex Doppler endosonography in the diagnosis of splenic vein, portal vein, and portosystemic shunt thrombosis. Gastrointest Endosc 1995;42:19-26.
44. Van Gansbeke D, Avni EF, Delcour C, Engelholm L, Struyven J. Sonographic features of portal vein thrombosis. AJR Am J Roentgenol 1985; 144:749-752.
45. Bach AM, Hann LE, Brown KT, Getrajdman GI, Herman SK, Fong Y, et al. Portal vein evaluation with US: Comparison to angiography combined with CT arterial portography. Radiology 1996;201:149-154.
46. Mathieu D, Vasile N, Grenier P. Portal thrombosis: Dynamic CT features and course. Radiology 1985;154:737-741.
47. Chou CK, Mak CW, Tzeng WS, Chang JM. CT of small bowel ischemia. Abdom Imaging 2004;29:18-22.
48. Cerri GG, Habr-Gama A, Paranagua-Vezozzo D, Machado MC, Pinotti HW, Magalhaes A. Doppler demonstration of cystic vein dilatation secondary to portal vein thrombosis. Surg Endosc 1991;5:92-93.
49. Baril N, Wren S, Radin R, Ralls P, Stain S. The role of anticoagulation in pylephlebitis. Am J Surg 1996;172:449-452; discussion 452-443.
50. Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 2004;351:268-277.
51. Hassn AM, Al-Fallouji MA, Ouf TI, Saad R. Portal vein thrombosis following splenectomy. Br J Surg 2000;87:362-373.
52. Lagasse JP, Bahallah ML, Salem N, Debillon G, Labarriere D, Serve MP, et al. Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients. [in French] Gastroenterol Clin Biol 1997;21:919-923.
53. de Franchis R. Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005;43:167-176.
54. Prandoni P, Lensing AWA, Prins MH, Bernardi E, Marchiori A, Bagatella P, et al. Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002;137:955-960.
55. Hollingshead M, Burke CT, Mauro MA, Weeks SM, Dixon RG, Jaques PF. Transcatheter thrombolytic therapy for acute mesenteric and portal vein thrombosis. J Vasc Interv Radiol 2005;16:651-661.
56. Malkowski P, Pawlak J, Michalowicz B, Szczerban J, Wroblewski T, Leowska E, et al. Thrombolytic treatment of portal thrombosis. Hepatogastroenterology 2003;50:2098-2100.
57. Grisham A, Lohr J, Guenther JM, Engel AM. Deciphering mesenteric venous thrombosis: Imaging and treatment. Vasc Endovascular Surg 2005;39:473-479.
58. Brunaud L, Antunes L, Collinet-Adler S, Marchal F, Ayav A, Bresler L, et al. Acute mesenteric venous thrombosis: Case for nonoperative management. J Vasc Surg 2001;34:673-679.
59. Abdu RA, Zakhour BJ, Dallis DJ. Mesenteric venous thrombosis-1911 to 1984. Surgery 1987;101:383-388.
60. Joh JH, Kim DI. Mesenteric and portal vein thrombosis: Treated with early initiation of anticoagulation. Eur J Vasc Endovasc Surg 2005;29: 204-208.
61. Eugene C, Valla D, Wesenfelder L, Fingerhut A, Bergue A, Merrer J, et al. Small intestinal stricture complicating superior mesenteric vein thrombosis. A study of three cases. Gut 1995;37:292-295.
62. Condat B, Vilgrain V, Asselah T, O'Toole D, Rufat P, Zappa M, et al. Portal cavernoma-associated cholangiopathy: A clinical and MR cholangiography coupled with MR portography imaging study. HEPATOLOGY 2003;37:1302-1308.
63. Khuroo MS, Yattoo GN, Zargar SA, Javid G, Dar MY, Khan BA, et al. Biliary abnormalities associated with extrahepatic portal venous obstruction. HEPATOLOGY 1993;17:807-813.
64. Condat B, Pessione F, Hillaire S, Denninger MH, Guillin MC, Poliquin M, et al. Current outcome of portal vein thrombosis in adults: Risk and benefit of anticoagulant therapy. Gastroenterology 2001;120:490-497.
65. Minguez B, Garcia-Pagan JC, Bosch J, Turnes J, Alonso J, Rovira A, et al. Noncirrhotic portal vein thrombosis exhibits neuropsychological and MRchanges consistent with minimal hepatic encephalopathy. HEPATOLOGY 2006;43:707-714.
66. Gupta D, Vijaya DR, Gupta R, Dhiman RK, Bhargava M, Verma J, et al. Prevalence of hepatopulmonary syndrome in cirrhosis and extrahepatic portal venous obstruction. Am J Gastroenterol 2001;96:3395-3399.
67. Ueno N, Sasaki A, Tomiyama T, Tano S, Kimura K. Color Doppler ultrasonography in the diagnosis of cavernous transformation of the portal vein. J Clin Ultrasound 1997;25:227-233.
68. Dumortier J, Vaillant E, Boillot O, Poncet G, Henry L, Scoazec JY, et al. Diagnosis and treatment of biliary obstruction caused by portal cavernoma. Endoscopy 2003;35:446-450.
69. Palazzo L, Hochain P, Helmer C, Cuillerier E, Landi B, Roseau G, et al. Biliary varices on endoscopic ultrasonography: Clinical presentation and outcome. Endoscopy 2000;32:520-524.
70. Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. HEPATOLOGY 2007;46:322-338.
71. Orr DW, Harrisson PM, Karani J, Rela M, Heaton ND, O'Grady JG, et al. Chronic portomesenteric and portosplenomesenteric venous thrombosis: evaluation of long term follow-up and determinants of survival [Abstract]. HEPATOLOGY 2005;42:212A.
72. Kahn D, Krige JE, Terblanche J, Bornman PC, Robson SC. A 15-year experience of injection sclerotherapy in adult patients with extrahepatic portal venous obstruction. Ann Surg 1994;219:34-39.
73. Vleggaar FP, van Buuren HR, Schalm SW. Endoscopic sclerotherapy for bleeding oesophagogastric varices secondary to extrahepatic portal vein obstruction in an adult Caucasian population. Eur J Gastroenterol Hepatol 1998;10:81-85.
74. Orloff MJ, Orloff MS, Girard B, Orloff SL. Bleeding esophagogastric varices from extrahepatic portal hypertension: 40 years' experience with portal-systemic shunt. J Am Coll Surg 2002;194:717-728; discussion 728-730.
75. Warren WD, Henderson JM, Millikan WJ, Galambos JT, Bryan FC. Management of variceal bleeding in patients with noncirrhotic portal vein thrombosis. Ann Surg 1988;207:623-634.
76. Senzolo M, Tibbals J, Cholongitas E, Triantos CK, Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006;23:767-775.
77. Kitchens CS, Weidner MH, Lottenberg R. Chronic oral anticoagulant therapy for extrahepatic visceral thrombosis is safe. J Thromb Thrombolysis 2007;23:223-228.
78. Chaudhary A, Dhar P, Sarin SK, Sachdev A, Agarwal AK, Vij JC, et al. Bile duct obstruction due to portal biliopathy in extrahepatic portal hypertension: Surgical management. Br J Surg 1998;85:326-329.
79. Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, Hashizume M, et al. Consensus on extra-hepatic portal vein obstruction. Liver Int 2006;26:512-519.
80. Shinohara T, Ando H, Watanabe Y, Seo T, Harada T, Kaneko K. Extrahepatic portal vein morphology in children with extrahepatic portal hypertension assessed by 3-dimensional computed tomographic portography: A new etiology of extrahepatic portal hypertension. J Pediatr Surg 2006;41:812-816.
81. Balta G, Altay C, Gurgey A. PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol 2002;71:89-93.
82. Dubuisson C, Boyer-Neumann C, Wolf M, Meyer D, Bernard O. Protein C, protein S and antithrombin III in children with portal vein obstruction. J Hepatol 1997;27:132-135.
83. El-Karaksy H, El-Koofy N, El-Hawary M, Mostafa A, Aziz M, El-Shabrawi M, et al. Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. Ann Hematol 2004;83:712-715.
84. Heller C, Schobess R, Kurnik K, Junker R, Gunther G, Kreuz W, et al. Abdominal venous thrombosis in neonates and infants: Role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group. Br J Haematol 2000;111:534-539.
85. Pinto RB, Silveira TR, Rosling L, Bandinelli E. Thrombophilic disorders in children and adolescents with portal vein thrombosis. [in Portugese] J Pediatr (Rio J) 2003;79:165-172.
86. Yachha SK, Aggarwal R, Sharma BC, Misra RN, Aggarwal A, Naik SR. Functional protein C and anti-cardiolipin antibody in children with portal vein thrombosis. Indian J Gastroenterol 2001;20:47-49.
87. Mack CL, Superina RA, Whitington PF. Surgical restoration of portal flow corrects procoagulant and anticoagulant deficiencies associated with extrahepatic portal vein thrombosis. J Pediatr 2003;142:197-199.
88. Morag I, Epelman M, Daneman A, Moineddin R, Parvez B, Shechter T, et al. Portal vein thrombosis in the neonate: Risk factors, course, and outcome. J Pediatr 2006;148:735-739.
89. Bellomo-Brandao MA, Morcillo AM, Hessel G, Cardoso SR, Servidoni Mde F, da-Costa-Pinto EA. Growth assessment in children with extrahepatic portal vein obstruction and portal hypertension. Arq Gastroenterol 2003;40:247-250.
90. Zargar SA, Javid G, Khan BA, Yattoo GN, Shah AH, Gulzar GM, et al. Endoscopic ligation compared with sclerotherapy for bleeding esophageal varices in children with extrahepatic portal venous obstruction. HEPATOLOGY 2002;36:666-672.
91. Pande GK, Reddy VM, Kar P, Sahni P, Berry M, Tandon BN, et al. Operations for portal hypertension due to extrahepatic obstruction: results and 10 year follow up. Br Med J (Clin Res Ed) 1987;295:1115-1117.
92. Superina R, Bambini DA, Lokar J, Rigsby C, Whitington PF. Correction of extrahepatic portal vein thrombosis by the mesenteric to left portal vein bypass. Ann Surg 2006;243:515-521.
93. Okuda K, Ohnishi K, Kimura K, Matsutani S, Sumida M, Goto N, et al. Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985;89:279-286.
94. Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005;54:691-697.
95. Tublin ME, Dodd GD 3rd, Baron RL. Benign and malignant portal vein thrombosis: Differentiation by CT characteristics. AJR Am J Roentgenol 1997;168:719-723.
96. Rossi S, Rosa L, Ravetta V, Cascina A, Quaretti P, Azzaretti A, et al. Contrast-enhanced versus conventional and color Doppler sonography for the detection of thrombosis of the portal and hepatic venous systems. AJR Am J Roentgenol 2006;186:763-773.
97. Nonami T, Yokoyama I, Iwatsuki S, Starzl TE. The incidence of portal vein thrombosis at liver transplantation. HEPATOLOGY 1992;16:1195-1198.
98. Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D'Andrea G, et al. Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. HEPATOLOGY 2000;31:345-348.
99. Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Sacco M, Martino R, et al. Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: Role of genetic thrombophilia. Endoscopy 2002;34:535-538.
100. Cavallari A, Vivarelli M, Bellusci R, Jovine E, Mazziotti A, Rossi C. Treatment of vascular complications following liver transplantation: multidisciplinary approach. Hepatogastroenterology 2001;48:179-183.
101. Settmacher U, Nussler NC, Glanemann M, Haase R, Heise M, Bechstein WO, et al. Venous complications after orthotopic liver transplantation. Clin Transplant 2000;14:235-241.
102. Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Venoocclusive disease of the liver after marrow transplantation: Histological correlates of clinical signs and symptoms. HEPATOLOGY 1994;19: 1171-1180.
103. DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathioprine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: The role of glutathione and relevance to hepatic venooclusive disease. HEPATOLOGY 1996;23:589-599.
104. DeLeve LD, Ito I, Bethea NW, McCuskey MK, Wang X, McCuskey RS. Embolization by sinusoidal lining cell obstructs the microcirculation in rat sinusoidal obstruction syndrome. Am J Physiol Gastrointest Liver Physiol 2003;284:G1045-G1052.
105. McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation - a cohort study of 355 patients. Ann Intern Med 1993;118:255-267.
106. Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Venoocclusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: Incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999;5:306-315.
107. Carreras E, Rosinol L, Terol MJ, Alegre A, de Arriba F, Garcia-Larana J, et al. Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myeloma patients. Biol Blood Marrow Transplant 2007;13:1448-1454.
108. McDonald GB. Liver disease of uncertain cause. Bone Marrow Transplant 2004;33:977-978.
109. Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987;44:778-783.
110. Blostein MD, Paltiel OB, Thibault A, Rybka WB. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant 1992;10:439-443.
111. Hommeyer SC, Teefey SA, Jacobson AF, Higano CS, Bianco JA, Colacurcio CJ, et al. Venocclusive disease of the liver: Prospective study of US evaluation. Radiology 1992;184:683-686.
112. Teefey SA, Brink JA, Borson RA, Middleton WD. Diagnosis of venoocclusive disease of the liver after bone marrow transplantation: Value of duplex sonography. Am J Roentgenol 1995;164:1397-1401.
113. McCarville MB, Hoffer FA, Howard SC, Goloubeva O, Kauffman WM. Hepatic veno-occlusive disease in children undergoing bone-marrow transplantation: Usefulness of sonographic findings. Pediatr Radiol 2001; 31:102-105.
114. Lassau N, Leclere J, Auperin A, Bourhis JH, Hartmann O, Valteau-Couanet D, et al. Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: Value of gray-scale and Doppler US in 100 patients. Radiology 1997;204:545-552.
115. Lassau N, Auperin A, Leclere J, Bennaceur A, Valteau-Couanet D, Hartmann O. Prognostic value of doppler-ultrasonography in hepatic venoocclusive disease. Transplantation 2002;74:60-66.
116. Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D, et al. Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995;59:1015-1022.
117. Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J, et al. Transjugular liver biopsy in BMT. Bone Marrow Transplant 1993;11: 21-26.
118. Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, Mc-Donald GB. Venoocclusive disease of the liver: Development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993;11:1729-1736.
119. McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 1985;36:603-608.
120. Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, et al. Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: A prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998;92:3599-3604.
121. Ganem G, Saint-Marc Girardin MF, Kuentz M, Cordonnier C, Morinello G, Teboul C, et al. Venocclusive disease of the liver after allogeneic bone marrow transplantation in man. Int J Radiat Oncol Biol Phys 1988; 14:879-884.
122. Hasegawa S, Horibe K, Kawabe T, Kato K, Kojima S, Matsuyama T, et al. Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: Incidence, onset time and risk factors. Bone Marrow Transplant 1998;22:1191-1197.
123. McDermott WV, Stone MD, Bothe A Jr, Trey C. Budd-Chiari syndrome. Historical and clinical review with an analysis of surgical corrective procedures. Am J Surg 1984;147:463-467.
124. Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, et al. Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003;102:1578-1582.
125. Dulley FL, Kanfer EJ, Appelbaum FR, Amos D, Hill RS, Buckner CD, et al. Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation 1987;43:870-873.
126. Reiss U, Cowan M, McMillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002;24:746-750.
127. Frickhofen N, Wiesneth M, Jainta C, Hertenstein B, Heymer B, Bianchi L, et al. Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83:1998-2004.
128. Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, et al. Hepatitis C virus infection and bone marrow transplantation: A cohort study with 10-year follow-up. HEPATOLOGY 1999;29:1893-1899.
129. Cordonnier C, Maury S, Esperou H, Pautas C, Beaune J, Rodet M, et al. Do minitransplants have minicosts? A cost comparison between myeloablative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant 2005;36:649-654.
130. Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch HG, et al. Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: A study of 193 patients. Blood 2004;103:78-84.
131. Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood 1990;76:1867-1871.
132. DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: Role of glutathione and site of metabolic activation. HEPATOLOGY 1996;24:830-837.
133. McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, et al. Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003;101: 2043-2048.
134. McDonald GB, McCune JS, Batchelder A, Cole SL, Phillips B, Ren AG, et al. Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clin Pharmacol Ther 2005;78:298-308.
135. Salinger DH, McCune JS, Ren AG, Shen DD, Slattery JT, Phillips B, et al. Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: A Bayesian pharmacokinetic approach. Clin Cancer Res 2006;12:4888-4898.
136. Grochow LB. Busulfan disposition: The role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20:18-25.
137. Demirer T, Buckner CD, Appelbaum FR, Bensinger WI, Sanders J, Lambert K, et al. Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: Phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996; 17:491-495.
138. Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE. A limited sample strategy for pharmacokinetic therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002;8:619-624.
139. Hassan M, Ehrsson H, Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma 1996;22:395-407.
140. Meéresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L, et al. Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: A study in 136 children. Bone Marrow Transplant 1992;10:135-141.
141. Shimoni A, Bielorai B, Toren A, Hardan I, Avigdor A, Yeshuran M, et al. Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: Myeloablation with reduced toxicity. Exp Hematol 2003;31:428-434.
142. Lee J-H, Choi S-J, Lee J-H, Kim S-E, Park C-J, Chi H-S, et al. Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005;84:321-330.
143. Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, et al. Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: Decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002;8:493-500.
144. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, et al. Pharmacokinetics of busulfan: Correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989;25:55-61.
145. Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, et al. Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001;28:743-751.
146. Schuler US, Ehrsam M, Schneider A, Schmidt H, Deeg J, Ehninger G. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant 1998;22:241-244.
147. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, et al. Marrow transplantation for chronic myeloid leukemia: The influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89:3055-3060.
148. Zwaveling J, Bredius RGM, Cremers SCLM, Ball LM, Lankester AC, Teepe-Twiss IM, et al. Intravenous busulfan in children prior to stem cell transplantation: Study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005;35:17-23.
149. Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, et al. Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003;102:820-826.
150. DeLima M, Ghaddar H, Pierce S, Estey E. Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol 1996;93:89-95.
151. Hagglund H, Remberger M, Klaesson S, Lonnqvist B, Ljungman P, Ringden O. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998;92:4568-4572.
152. Attal M, Huguet F, Rubie H, Charlet JP, Schlaifer D, Huynh A, et al. Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline - a prospective, randomized trial. Blood 1993;82: 732-736.
153. Rosenthal J, Sender L, Secola R, Killen R, Millerick M, Murphy L, et al. Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996;18:185-191.
154. Bearman SI, Hinds MS, Wolford JL, Petersen FB, Nugent DL, Slichter SJ, et al. A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990;5:407-411.
155. Marsa-Vila L, Gorin NC, Laporte JP, Labopin M, Dupuy-Montbrun MC, Fouillard L, et al. Prophylactic heparin does not prevent liver venoocclusive disease following autologous bone marrow transplantation. Eur J Haematol 1991;47:346-354.
156. Imran H, Tleyjeh IM, Zirakzadeh A, Rodriguez V, Khan SP. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transplant 2006;37: 677-686.
157. Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, et al. Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998;128:975-981.
158. Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A, et al. The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000;64:32-38.
159. Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, et al. Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002;100:1977-1983.
160. Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS, et al. A randomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic venoocclusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;29:137-143.
161. Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007;13:206-217.
162. Gluckman E, Jolivet I, Scrobohaci ML, Devergie A, Traineau R, Bourdeau-Esperou H, et al. Role of PGE1 to prevent veno-occlusive disease of the liver after bone marrow transplantation. Nouv Rev Fr Hematol 1990;32:1-3.
163. Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB. A phase-I phase-II study of prostaglandin E1 for the prevention of hepatic venoocclusive disease after bone marrow transplantation. Br J Haematol 1993; 84:724-730.
164. Clift RA, Bianco JA, Appelbaum FR, Buckner CD, Singer JW, Bakke L, et al. A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993;82:2025-2030.
165. Barkholt L, Remberger M, Hassan Z, Fransson K, Omazic B, Svahn BM, et al. A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008;41:785-790.
166. Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997;89:1501-1506.
167. Kulkarni S, Rodriguez M, Lafuente A, Mateos P, Mehta J, Singhal S, et al. Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Bone Marrow Transplant 1999; 23:803-807.
168. Hagglund H, Ringden O, Ljungman P, Winiarski J, Ericzon B, Tyden G. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation. Transplant Proc 1995;27:3535.
169. Hagglund H, Ringden O, Ericzon BG, Duraj F, Ljungman P, Lonnqvist B, et al. Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Transplantation 1996;62: 1076-1080.
170. Hohlfeld T, Strobach H, Schror K. Stimulation of prostacyclin synthesis by defibrotide: Improved contractile recovery from myocardial "stunning". J Cardiovasc Pharmacol 1991;17:108-115.
171. Biagi G, Legnani C, Rodorigo G, Coccheri S. Modulation of arachidonate metabolite generation in human blood by oral defibrotide. Arzneimittelforschung 1991;41:511-514.
172. San T, Moini H, Emerk K, Bilsel S. Protective effect of defibrotide on perfusion induced endothelial damage. Thromb Res 2000;99:335-341.
173. Masini E, Lupini M, Mugnai L, Raspanti S, Mannaioni PF. Polydeoxyribonucleotides and nitric oxide release from guinea-pig hearts during ischaemia and reperfusion. Br J Pharmacol 1995;115:629-635.
174. Berti F, Rossoni G, Della Bella D, Villa LM, Buschi A, Trento F, et al. Nitric oxide and prostacyclin influence coronary vasomotor tone in perfused rabbit heart and modulate endothelin-1 activity. J Cardiovasc Pharmacol 1993;22:321-326.
175. Pellegatta F, Lu Y, Radaelli A, Zocchi MR, Ferrero E, Chierchia S, et al. Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion. Br J Pharmacol 1996;118:471-476.
176. Klocking HP. Acute t-PA release by defibrotide. Thromb Res 1992;66: 779-785.
177. Bianchi G, Barone D, Lanzarotti E, Tettamanti R, Porta R, Moltrasio D, et al. Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993;238:327-334.
178. Abbate R, Gori AM, Martini F, Attanasio M, Comeglio P, Giusti B, et al. Defibrotide reduces monocyte PAI-2 and procoagulant activity. Semin Thromb Hemost 1995;21:245-250.
179. Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003;17:1636-1642.
180. Lefer AM, Aoki N, Mulloy D. Coronary endothelium-protective effects of defibrotide in ischaemia and reperfusion. Naunyn Schmiedebergs Arch Pharmakol 1990;341:246-250.
181. Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppensteadt D, et al. Treatment of severe veno-occlusive disease with defibrotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998;92:737-744.
182. Chopra R, Eaton JD, Grassi A, Potter M, Shaw B, Salat C, et al. Defibrotide for the treatment of hepatic veno-occlusive disease: Results of the European compassionate-use study. Br J Haematol 2000;111:1122-1129.
183. Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, et al. Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: Response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002;100:4337-4343.
184. Chalandon Y, Roosnek E, Mermillod B, Newton A, Ozsahin H, Wacker P, et al. Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10:347-354.
185. Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, et al. Defibrotide in the treatment of children with veno-occlusive disease (VOD): A retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004;33:189-195.
186. Fried MW, Connaghan DG, Sharma S, Martin LG, Devine S, Holland K, et al. Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. HEPATOLOGY 1996;24:588-591.
187. Azoulay D, Castaing D, Lemoine A, Hargreaves GM, Bismuth E. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant 2000;25:987-992.
188. Wang X, Kanel G, DeLeve LD. Support of sinusoidal endothelial cell glutathione prevents hepatic venoocclusive disease in vivo. HEPATOLOGY 2000;31:428-434.
189. DeLeve LD, Wang X, Kanel GC, Tokes ZA, Tsai J, Ito Y, et al. Decreased Hepatic Nitric Oxide Production Contributes to the Development of Rat Sinusoidal Obstruction Syndrome. HEPATOLOGY 2003;38:900-908.
190. DeLeve LD, Wang X, Tsai J, Kanel GC, Strasberg SM, Tokes ZA. Prevention of sinusoidal obstruction syndrome (hepatic venoocclusive disease) in the rat by matrix metalloproteinase inhibitors. Gastroenterology 2003;125:882-890.
191. Koenecke C, Kleine M, Schrem H, Krug U, Nashan B, Neipp M, et al. Sinusoidal obstruction syndrome of the liver after hematopoietic stem cell transplantation: Decision making for orthotopic liver transplantation. Int J Hematol 2006;83:271-274.
192. Mellgren K, Fasth A, Saalman R, Olausson M, Abrahamsson J. Liver transplantation after stem cell transplantation with the same living donor in a monozygotic twin with acute myeloid leukemia. Ann Hematol 2005; 84:755-757.
193. Kim I-D, Egawa H, Marui Y, Kaihara S, Haga H, Lin Y-W, et al. A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation. Am J Transplant 2002; 2:796-800.
194. Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: A review by an expert panel. J Hepatol 2003;38:364-371.
195. Shrestha SM, Okuda K, Uchida T, Maharjan KG, Shrestha S, Joshi BL, et al. Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol 1996;11:170-179.
196. Valla D. Hepatic venous outflow tract obstruction etipathogenesis: Asia versus the West. J Gastroenterol Hepatol 2004;19:S204-S211.
197. Ludwig J, Hashimoto E, McGill D, Heerden Jv. Classification of hepatic venous outflow obstruction:aMbiguous terminology of the Budd-Chiari syndrome. Mayo Clin Proc 1990;65:51-55.
198. Mehrotra G, Singh RP, Krishna A, Singh BK. Pyogenic liver abscess causing acute Budd-Chiari syndrome. Ann Trop Paediatr 1992;12:451-453.
199. Uddin W, Ramage JK, Portmann B, Wilson P, Benjamin I, Tan KC, et al. Hepatic venous outflow obstruction in patients with polycystic liver disease: Pathogenesis and treatment. Gut 1995;36:142-145.
200. Rangheard AS, Vilgrain V, Audet P, O'Toole D, Vullierme MP, Valla D, et al. Focal nodular hyperplasia inducing hepatic vein obstruction. AJR Am J Roentgenol 2002;179:759-762.
201. Kubo T, Shibata T, Itoh K, Maetani Y, Isoda H, Hiraoka M, et al. Outcome of percutaneous transhepatic venoplasty for hepatic venous outflow obstruction after living donor liver transplantation. Radiology 2006;239:285-290.
202. Wang SL, Sze DY, Busque S, Razavi MK, Kee ST, Frisoli JK, et al. Treatment of hepatic venous outflow obstruction after piggyback liver transplantation. Radiology 2005;236:352-359.
203. Balian A, Valla D, Naveau S, Musset D, Coue O, Lemaigre G, et al. Post-traumatic membranous obstruction of the inferior vena cava associated with a hypercoagulable state. J Hepatol 1998;28:723-726.
204. Kim PN, Mitchell DG, Outwater EK. Budd-Chiari syndrome: Hepatic venous obstruction by an elevated diaphragm. Abdom Imaging 1999;24: 267-271.
205. Markert DJ, Shanmuganathan K, Mirvis SE, Nakajima Y, Hayakawa M. Budd-Chiari syndrome resulting from intrahepatic IVC compression secondary to blunt hepatic trauma. Clin Radiol 1997;52:384-387.
206. Dilawari JB, Bambery P, Chawla Y, Kaur U, Bhusnurmath SR, Malhotra HS, et al. Hepatic outflow obstruction (Budd-Chiari syndrome). Experience with 177 patients and a review of the literature. Medicine (Baltimore) 1994;73:21-36.
207. Bayraktar Y, Balkanci F, Bayraktar M, Calguneri M. Budd-Chiari syndrome: a common complication of Behcet's disease. Am J Gastroenterol 1997;92:858-862.
208. Dayal S, Pati HP, Pande GK, Sharma MP, Saraya AK. Multilineage hemopoietic stem cell defects in Budd Chiari syndrome. J Hepatol 1997; 26:293-297.
209. Deltenre P, Denninger MH, Hillaire S, Guillin MC, Casadevall N, Briere J, et al. Factor V Leiden related Budd-Chiari syndrome. Gut 2001;48: 264-268.
210. Hirshberg B, Shouval D, Fibach E, Friedman G, Ben-Yehuda D. Flow cytometric analysis of autonomous growth of erythroid precursors in liquid culture detects occult polycythemia vera in the Budd-Chiari syndrome. J Hepatol 2000;32:574-578.
211. Kumar SI, Kumar A, Srivastava S, Saraswat VA, Aggarwal R. Low frequency of factor V Leiden and prothrombin G20210A mutations in patients with hepatic venous outflow tract obstruction in northern India: A case-control study. Indian J Gastroenterol 2005;24:211-215.
212. Lin GL, Xu PQ, Qi H, Lian JH, Zheng H, Dang XW. Relations of Budd-Chiari syndrome to prothrombin gene mutation. Hepatobiliary Pancreat Dis Int 2004;3:214-218.
213. Valla D, Casadevall N, Lacombe C, Varet B, Goldwasser E, Franco D, et al. Primary myeloproliferative disorder and hepatic vein thrombosis. A prospective study of erythroid colony formation in vitro in 20 patients with Budd-Chiari syndrome. Ann Intern Med 1985;103:329-334.
214. Patel RK, Lea NC, Heneghan MA, Westwood NB, Milojkovic D, Thanigaikumar M, et al. Prevalence of the activating JAK2 tyrosine kinase mutation V617F in the Budd-Chiari syndrome. Gastroenterology 2006; 130:2031-2038.
215. Smalberg JH, Murad SD, Braakman E, Valk PJ, Janssen HL, Leebeek FW. Myeloproliferative disease in the pathogenesis and survival of Budd-Chiari syndrome. Haematologica 2006;91:1712-1713.
216. Aggarwal R, Ravishankar B, Misra R, Aggarwal A, Dwivedi S, Naik SR. Significance of elevated IgG anticardiolipin antibody levels in patients with Budd-Chiari syndrome. Am J Gastroenterol 1998;93:954-957.
217. Espinosa G, Font J, Garcia-Pagan JC, Tassies D, Reverter JC, Gaig C, et al. Budd-Chiari syndrome secondary to antiphospholipid syndrome: clinical and immunologic characteristics of 43 patients. Medicine (Baltimore) 2001;80:345-354.
218. Mangia A, Margaglione M, Cascavilla I, Gentile R, Cappucci G, Facciorusso D, et al. Anticardiolipin antibodies in patients with liver disease. Am J Gastroenterol 1999;94:2983-2987.
219. Bosy-Westphal A, Ruschmeyer M, Czech N, Oehler G, Hinrichsen H, Plauth M, et al. Determinants of hyperhomocysteinemia in patients with chronic liver disease and after orthotopic liver transplantation. Am J Clin Nutr 2003;77:1269-1277.
220. Li XM, Wei YF, Hao HL, Hao YB, He LS, Li JD, et al. Hyperhomocysteinemia and the MTHFR C677T mutation in Budd-Chiari syndrome. Am J Hematol 2002;71:11-14.
221. Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995;333:1253-1258.
222. Valla D, Dhumeaux D, Babany G, Hillon P, Rueff B, Rochant H, et al. Hepatic vein thrombosis in paroxysmal nocturnal hemoglobinuria. A spectrum from asymptomatic occlusion of hepatic venules to fatal Budd-Chiari syndrome. Gastroenterology 1987;93:569-575.
223. Zylberberg H, Valla D, Viguie F, Casadevall N. Budd-Chiari syndrome associated with 5q deletion and hypereosinophilia. J Clin Gastroenterol 1996;23:66-68.
224. Young ID, Clark RN, Manley PN, Groll A, Simon JB. Response to steroids in Budd-Chiari syndrome caused by idiopathic granulomatous venulitis. Gastroenterology 1988;94:503-507.
225. Rahhal RM, Pashankar DS, Bishop WP. Ulcerative colitis complicated by ischemic colitis and Budd Chiari syndrome. J Pediatr Gastroenterol Nutr 2005;40:94-97.
226. Valla D, Le MG, Poynard T, Zucman N, Rueff B, Benhamou JP. Risk of hepatic vein thrombosis in relation to recent use of oral contraceptives. A case-control study. Gastroenterology 1986;90:807-811.
227. Khuroo MS, Datta DV. Budd-Chiari syndrome following pregnancy. Report of 16 cases, with roentgenologic, hemodynamic and histologic studies of the hepatic outflow tract. Am J Med 1980;68:113-121.
228. Parker RGF. Occlusion of the hepatic veins in man. Medicine (Baltimore) 1959;38:369-402.
229. Hadengue A, Poliquin M, Vilgrain V, Belghiti J, Degott C, Erlinger S, et al. The changing scene of hepatic vein thrombosis: Recognition of asymptomatic cases. Gastroenterology 1994;106:1042-1047.
230. Murad SD, Valla DC, de Groen PC, Zeitoun G, Hopmans JA, Haagsma EB, et al. Determinants of survival and the effect of portosystemic shunting in patients with Budd-Chiari syndrome. HEPATOLOGY 2004;39:500-508.
231. Okuda H, Yamagata H, Obata H, Iwata H, Sasaki R, Imai F, et al. Epidemiological and clinical features of Budd-Chiari syndrome in Japan. J Hepatol 1995;22:1-9.
232. Cazals-Hatem D, Vilgrain V, Genin P, Denninger MH, Durand F, Belghiti J, et al. Arterial and portal circulation and parenchymal changes in Budd-Chiari syndrome: A study in 17 explanted livers. HEPATOLOGY 2003;37:510-519.
233. Mahmoud AEA, Helmy AS, Billingham S, Elias E. Poor prognosis and limited therapeutic options in patients with Budd-Chiari syndrome and portal venous system thrombosis. Eur J Gastroenterol Hepatol 1997;9: 485-489.
234. Tanaka M, Wanless IR. Pathology of the liver in Budd-Chiari syndrome: portal vein thrombosis and the histogenesis of veno-centric cirrhosis, veno-portal cirrhosis, and large regenerative nodules. HEPATOLOGY 1998; 27:488-496.
235. Kreel L, Freston JW, Clain D. Vascular radiology in the Budd-Chiari syndrome. Br J Radiol 1967;40:755-759.
236. Wilson MW, Ring EJ, LaBerge JM, Kerlan RK, Gordon RL. Percutaneous transhepatic hepatic venography in the delineation and treatment of Budd-Chiari syndrome. J Vasc Interv Radiol 1996;7:133-138.
237. Fisher NC, McCafferty I, Dolapci M, Wali M, Buckels JA, Olliff SP, et al. Managing Budd-Chiari syndrome: A retrospective review of percutaneous hepatic vein angioplasty and surgical shunting. Gut 1999;44:568-574.
238. Tavill AS, Wood EJ, Kreel L, Jones EA, Gregory M, Sherlock S. The Budd-Chiari syndrome: Correlation between hepatic scintigraphy and the clinical, radiological, and pathological findings in nineteen cases of hepatic venous outflow obstruction. Gastroenterology 1975;68:509-518.
239. Lim JH, Park JH, Auh YH. Membranous obstruction of inferior vena cava: comparison of findings at sonography, CT, and venography. Am J Roentgenol 1992;159:515-520.
240. Miller WJ, Federle MP, Straub WH, Davis PL. Budd-Chiari syndrome: imaging with pathologic correlation. Abdom Imaging 1993;18:329-335.
241. Chawla Y, Kumar S, Dhiman RK, Suri S, Dilawari JB. Duplex Doppler sonography in patients with Budd-Chiari syndrome. J Gastroenterol Hepatol 1999;14:904-907.
242. Grant EG, Perrella R, Tessler FN, Lois J, Busuttil R. Budd-Chiari syndrome: The results of duplex and color Doppler imaging. AJR Am J Roentgenol 1989;152:377-381.
243. Millener P, Grant EG, Rose S, Duerinckx A, Schiller VL, Tessler FN, et al. Color Doppler imaging findings in patients with Budd-Chiari syndrome: Correlation with venographic findings. AJR Am J Roentgenol 1993;161:307-312.
244. Menu Y, Sebag G, Vigrain V, Arriveé L, Nahum H. Budd-Chiari syndrome: MR evaluation. Diagn Interv Radiol 1990;2:23-28.
245. Gupta S, Barter S, Phillips GW, Gibson RN, Hodgson HJ. Comparison of ultrasonography, computed tomography and 99mTc liver scan in diagnosis of Budd-Chiari syndrome. Gut 1987;28:242-247.
246. Baert AL, Fevery J, Marchal G, Goddeeris P, Wilms G, Ponette E, et al. Early diagnosis of Budd-Chiari syndrome by computed tomography and ultrasonography: Report of five cases. Gastroenterology 1983;84:587-595.
247. Mathieu D, Kracht M, Zafrani E, Dhumeaux D, Vasile N. Budd-Chiari syndrome. In: Ferrucci JR, Matthieu DG, eds. Advances in Hepatobiliary Radiology. St Louis, MO: C.V. Mosby Co.; 1990:3-28.
248. Van Beers B, Pringot J, Trigaux JP, Dautrebande J, Mathurin P. Hepatic heterogeneity on CT in Budd-Chiari syndrome: Correlation with regional disturbances in portal flow. Gastrointest Radiol 1988;13:61-66.
249. Solano FX, Young E, Talamo TS, Dekker A. Constrictive pericarditis mimicking Budd-Chiari syndrome. Am J Med 1986;80:113-115.
250. Kakar S, Kamath PS, Burgart LJ. Sinusoidal dilatation and congestion in liver biopsy: Is it always due to venous outflow impairment? Arch Pathol Lab Med 2004;128:901-904.
251. Rector WG, Xu YH, Goldstein L, Peters RL, Reynolds TB. Membranous obstruction of the inferior vena cava in the United States. Medicine (Baltimore) 1985;64:134-143.
252. Wanless I, Liu J, Butany J. Role of thrombosis in the pathogenesis of congestive hepatic fibrosis (cardiac cirrhosis). HEPATOLOGY 1995;21: 1232-2137.
253. DeLeve LD, Shulman HM, McDonald GB. Toxic injury to hepatic sinusoids: sinusoidal obstruction syndrome (veno-occlusive disease). Semin Liver Dis 2002;22:27-42.
254. Tang TJ, Batts KP, de Groen PC, van Hoek B, Haagsma EB, Hop WC, et al. The prognostic value of histology in the assessment of patients with Budd-Chiari syndrome. J Hepatol 2001;35:338-343.
255. Zeitoun G, Escolano S, Hadengue A, Azar N, El Younsi M, Mallet A, et al. Outcome of Budd-Chiari syndrome: A multivariate analysis of factors related to survival including surgical portosystemic shunting. HEPATOLOGY 1999;30:84-89.
256. Vons C, Smadja C, Franco D, Valla D, Rueff B, Benhamou JP. Successful pregnancy after Budd-Chiari syndrome. Lancet 1984;2:975.
257. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124.
258. Campbell DA, Rolles K, Jamieson N, O'Grady J, Wight D, Williams R, et al. Hepatic transplantation with perioperative and long term anticoagulation as treatment for Budd-Chiari syndrome. Surg Gynecol Obstet 1988;166:511-518.
259. Halff G, Todo S, Tzakis AG, Gordon RD, Starzl TE. Liver transplantation for the Budd-Chiari syndrome. Ann Surg 1990;211:43-49.
260. Cruz E, Ascher NL, Roberts JP, Bass NM, Yao FY. High incidence of recurrence and hematologic events following liver transplantation for Budd-Chiari syndrome. Clin Transplant 2005;19:501-506.
261. Hemming AW, Langer B, Greig P, Taylor BR, Adams R, Heathcote EJ. Treatment of Budd-Chiari syndrome with portosystemic shunt or liver transplantation. Am J Surg 1996;171:176-180; discussion 180-171.
262. Ringe B, Lang H, Oldhafer KJ, Gebel M, Flemming P, Georgii A, et al. Which is the best surgery for Budd-Chiari syndrome: Venous decompression or liver transplantation? A single-center experience with 50 patients. HEPATOLOGY 1995;21:1337-1344.
263. Shaked A, Goldstein RM, Klintmalm GB, Drazan K, Husberg B, Busuttil RW. Portosystemic shunt versus orthotopic liver transplantation for the Budd-Chiari syndrome. Surg Gynecol Obstet 1992;174:453-459.
264. Srinivasan P, Rela M, Prachalias A, Muiesan P, Portmann B, Mufti GJ, et al. Liver transplantation for Budd-Chiari syndrome. Transplantation 2002;73:973-977.
265. Mentha G, Giostra E, Majno PE, Bechstein WO, Neuhaus P, O'Grady J, et al. Liver transplantation for Budd-Chiari syndrome: A European study on 248 patients from 51 centres. J Hepatol 2006;44:520-528.
266. Zhang CQ, Fu LN, Xu L, Zhang GQ, Jia T, Liu JY, et al. Long-term effect of stent placement in 115 patients with Budd-Chiari syndrome. World J Gastroenterol 2003;9:2587-2591.
267. Plessier A, Sibert A, Consigny Y, Hakime A, Zappa M, Denninger MH, et al. Aiming at minimal invasiveness as a therapeutic strategy for Budd-Chiari syndrome. HEPATOLOGY 2006;44:1308-1316.
268. Sharma S, Texeira A, Texeira P, Elias E, Wilde J, Olliff SP. Pharmacological thrombolysis in Budd Chiari syndrome: A single centre experience and review of the literature. J Hepatol 2004;40:172-180.
269. Hernandez-Guerra M, Lopez E, Bellot P, Piera C, Turnes J, Abraldes JG, et al. Systemic hemodynamics, vasoactive systems, and plasma volume in patients with severe Budd-Chiari syndrome. HEPATOLOGY 2006;43:27-33.
270. Valla D, Hadengue A, el Younsi M, Azar N, Zeitoun G, Boudet MJ, et al. Hepatic venous outflow block caused by short-length hepatic vein stenoses. HEPATOLOGY 1997;25:814-819.
271. Okuda K. Inferior vena cava thrombosis at its hepatic portion (obliterative hepatocavopathy). Semin Liver Dis 2002;22:15-26.
272. Griffith JF, Mahmoud AE, Cooper S, Elias E, West RJ, Olliff SP. Radiological intervention in Budd-Chiari syndrome: Techniques and outcome in 18 patients. Clin Radiol 1996;51:775-784.
273. Martin LG, Henderson JM, Millikan WJ, Casarella WJ, Kaufman SL. Angioplasty for long-term treatment of patients with Budd-Chiari syndrome. AJR Am J Roentgenol 1990;154:1007-1010.
274. Núñez O, de la Cruz G, Molina J, Borrego GM, Marín I, Ponferrada A, et al. Interventional radiology, angioplasty and TIPS in Budd-Chiari syndrome. [in Spanish] Gastroenterol Hepatol 2003;26:461-464.
275. Pelage JP, Denys A, Valla D, Sibert A, Sauvanet A, Belghiti J, et al. Budd-Chiari syndrome due to prothrombotic disorder: Mid-term patency and efficacy of endovascular stents. Eur Radiol 2003;13:286-293.
276. Qiao T, Liu CJ, Liu C, Chen K, Zhang XB, Zu MH. Interventional endovascular treatment for Budd-Chiari syndrome with long-term follow-up. Swiss Med Wkly 2005;135:318-326.
277. Witte AM, Kool LJ, Veenendaal R, Lamers CB, van Hoek B. Hepatic vein stenting for Budd-Chiari syndrome. Am J Gastroenterol 1997;92: 498-501.
278. Lee BB, Villavicencio L, Kim YW, Do YS, Koh KC, Lim HK, et al. Primary Budd-Chiari syndrome: Outcome of endovascular management for suprahepatic venous obstruction. J Vasc Surg 2006;43:101-108.
279. Furui S, Sawada S, Irie T, Makita K, Yamauchi T, Kusano S, et al. Hepatic inferior vena cava obstruction: Treatment of two types with Gianturco expandable metallic stents. Radiology 1990;176:665-670.
280. Baijal SS, Roy S, Phadke RV, Agrawal DK, Kumar S, Choudhuri G. Management of idiopathic Budd-Chiari syndrome with primary stent placement: Early results. J Vasc Interv Radiol 1996;7:545-553.
281. Guan H. Diagnosis and treatment of membraneous obstruction of the inferior vena cava. [in Chinese] Zhonghua Wai Ke Za Zhi 1990;28:760-763, 783-764.
282. Kohli V, Pande GK, Dev V, Reddy KS, Kaul U, Nundy S. Management of hepatic venous outflow obstruction. Lancet 1993;342:718-722.
283. Sato M, Yamada R, Tsuji K, Kishi K, Terada M, Shioyama Y, et al. Percutaneous transluminal angioplasty in segmental obstruction of the hepatic inferior vena cava: Long-term results. Cardiovasc Intervent Radiol 1990;13:189-192.
284. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Kobayashi N. Segmental obstruction of the hepatic inferior vena cava treated by transluminal angioplasty. Radiology 1983;149:91-96.
285. Yang XL, Chen CR, Cheng TO. Nonoperative treatment of membranous obstruction of the inferior vena cava by percutaneous balloon transluminal angioplasty. Am Heart J 1992;124:405-412.
286. Bilbao JI, Pueyo JC, Longo JM, Arias M, Herrero JI, Benito A, et al. Interventional therapeutic techniques in Budd-Chiari syndrome. Cardiovasc Intervent Radiol 1997;20:112-119.
287. De BK, Biswas PK, Sen S, Das D, De KK, Das U, et al. Management of the Budd-Chiari syndrome by balloon cavoplasty. Indian J Gastroenterol 2001;20:151-154.
288. Khuroo MS, Al-Suhabani H, Al-Sebayel M, Al Ashgar H, Dahab S, Khan MQ, et al. Budd-Chiari syndrome: Long-term effect on outcome with transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol 2005;20:1494-1502.
289. Mishra TK, Routray SN, Behera M, Patnaik UK, Satapathy C. Percutaneous balloon angioplasty of membranous obstruction of the inferior vena cava. Indian Heart J 2003;55:362-364.
290. Tyagi S, Jain BL, Kumar N, Lahoti D, Arora R. Balloon dilatation of inferior vena cava stenosis in Budd-Chiari syndrome. J Assoc Physicians India 1996;44:378-380.
291. Wu T, Wang L, Xiao Q, Wang B, Li S, Li X, et al. Percutaneous balloon angioplasty of inferior vena cava in Budd-Chiari syndrome-R1. Int J Cardiol 2002;83:175-178.
292. Xiaoming Z, Zhonggao W. Interventional or semi-interventional treatment for Budd-Chiari syndrome. Chin Med Sci J 2003;18:111-115.
293. Xu K, Feng B, Zhong H, Zhang X, Su H, Li H, et al. Clinical application of interventional techniques in the treatment of Budd-Chiari syndrome. Chin Med J (Engl) 2003;116:609-615.
294. Langlet P, Valla D. Is surgical portosystemic shunt the treatment of choice in Budd-Chiari syndrome? Acta Gastroenterol Belg 2002;65:155-160.
295. Bachet JB, Condat B, Hagege H, Plessier A, Consigny Y, Belghiti J, et al. Long-term portosystemic shunt patency as a determinant of outcome in Budd-Chiari syndrome. J Hepatol 2007;46:60-68.
296. Panis Y, Belghiti J, Valla D, Benhamou JP, Fekete F. Portosystemic shunt in Budd-Chiari syndrome: Long-term survival and factors affecting shunt patency in 25 patients in Western countries. Surgery 1994;115:276-281.
297. Langlet P, Escolano S, Valla D, Coste-Zeitoun D, Denie C, Mallet A, et al. Clinicopathological forms and prognostic index in Budd-Chiari syndrome. J Hepatol 2003;39:496-501.
298. Feng LS, Peng QP, Li K, Ma XX, Zhao YF, Ye XX, et al. Management of severe Budd-Chiari syndrome: Report of 147 cases. Hepatobiliary Pancreat Dis Int 2004;3:522-525.
299. Savader SJ, Venbrux AC, Klein AS, Osterman FA. Percutaneous intervention in portosystemic shunts in Budd-Chiari syndrome. J Vasc Interv Radiol 1991;2:489-495.
300. Bismuth H, Sherlock DJ. Portasystemic shunting versus liver transplantation for the Budd-Chiari syndrome. Ann Surg 1991;214:581-589.
301. Ganger DR, Klapman JB, McDonald V, Matalon TA, Kaur S, Rosenblate H, et al. Transjugular intrahepatic portosystemic shunt (TIPS) for Budd-Chiari syndrome or portal vein thrombosis: Review of indications and problems. Am J Gastroenterol 1999;94:603-608.
302. Ryu RK, Durham JD, Krysl J, Shrestha R, Shrestha R, Everson GT, et al. Role of TIPS as a bridge to hepatic transplantation in Budd-Chiari syndrome. J Vasc Interv Radiol 1999;10:799-805.
303. Slakey DP, Klein AS, Venbrux AC, Cameron JL. Budd-Chiari syndrome: current management options. Ann Surg 2001;233:522-527.
304. Cejna M, Peck-Radosavljevic M, Schoder M, Thurnher S, Ba-Ssalamah A, Angermayr B, et al. Repeat interventions for maintenance of transjugular intrahepatic portosystemic shunt function in patients with Budd-Chiari syndrome. J Vasc Interv Radiol 2002;13:193-199.
305. Perello A, Garcia-Pagan JC, Gilabert R, Suarez Y, Moitinho E, Cervantes F, et al. TIPS is a useful long-term derivative therapy for patients with Budd-Chiari syndrome uncontrolled by medical therapy. HEPATOLOGY 2002;35:132-139.
306. Blokzijl H, de Knegt RJ. Long-term effect of treatment of acute Budd-Chiari syndrome with a transjugular intrahepatic portosytemic shunt. HEPATOLOGY 2002;35:1551-1552.
307. Mancuso A, Fung K, Mela M, Tibballs J, Watkinson A, Burroughs AK, et al. TIPS for acute and chronic Budd-Chiari syndrome: A single-centre experience. J Hepatol 2003;38:751-754.
308. Kavanagh PM, Roberts J, Gibney R, Malone D, Hegarty J, McCormick PA. Acute Budd-Chiari syndrome with liver failure: The experience of a policy of initial interventional radiological treatment using transjugular intrahepatic portosystemic shunt. J Gastroenterol Hepatol 2004;19: 1135-1139.
309. Attwell A, Ludkowski M, Nash R, Kugelmas M. Treatment of Budd-Chiari syndrome in a liver transplant unit, the role of transjugular intrahepatic porto-systemic shunt and liver transplantation. Aliment Pharmacol Ther 2004;20:867-873.
310. Rossle M, Olschewski M, Siegerstetter V, Berger E, Kurz K, Grandt D. The Budd-Chiari syndrome: Outcome after treatment with the transjugular intrahepatic portosystemic shunt. Surgery 2004;135:394-403.
311. Safka V, Hulek P, Krajina A, Dulicek P, Fejfar T, Jirkovsky V, et al. Budd-Chiari syndrome and TIPS-twelve years' experience. [in Czech] Cas Lek Cesk 2005;144(Suppl 3):38-42.
312. Molmenti EP, Segev DL, Arepally A, Hong J, Thuluvath PJ, Rai R, et al. The utility of TIPS in the management of Budd-Chiari syndrome. Ann Surg 2005;241:978-981; discussion 982-973.
313. Eapen CE, Velissaris D, Heydtmann M, Gunson B, Olliff S, Elias E. Favourable medium term outcome following hepatic vein recanalisation and/ or transjugular intrahepatic portosystemic shunt for Budd Chiari syndrome. Gut 2006;55:878-884.
314. Hernandez-Guerra M, Turnes J, Rubinstein P, Olliff S, Elias E, Bosch J, et al. PTFE-covered stents improve TIPS patency in Budd-Chiari syndrome. HEPATOLOGY 2004;40:1197-1202.
315. Henderson JM, Nagle A, Curtas S, Geisinger M, Barnes D. Surgical shunts and TIPS for variceal decompression in the 1990s. Surgery 2000; 128:540-547.
316. Jamieson NV, Williams R, Calne RY. Liver transplantation for Budd-Chiari syndrome, 1976-1990. Ann Chir 1991;45:362-365.
317. Segev DL, Nguyen GC, Locke JE, Simpkins CE, Montgomery RA, Maley WR, et al. Twenty years of liver transplantation for Budd-Chiari syndrome: A national registry analysis. Liver Transpl 2007;13:1285-1294.
318. Melear JM, Goldstein RM, Levy MF, Molmenti EP, Cooper B, Netto GJ, et al. Hematologic aspects of liver transplantation for Budd-Chiari syndrome with special reference to myeloproliferative disorders. Transplantation 2002;74:1090-1095.
319. Valla DC. Prognosis in Budd Chiari syndrome after re-establishing hepatic venous drainage. Gut 2006;55:761-763.
320. Min AD, Atillasoy EO, Schwartz ME, Thiim M, Miller CM, Bodenheimer HC. Reassessing the role of medical therapy in the management of hepatic vein thrombosis. Liver Transpl Surg 1997;3:423-429.
321. Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SHB, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137:947-954.
322. Havlioglu N, Brunt EM, Bacon BR. Budd-Chiari syndrome and hepatocellular carcinoma: A case report and review of the literature. Am J Gastroenterol 2003;98:201-204.
323. Moucari R, Rautou PE, Cazals-Hatem D, Geara A, Bureau C, Consigny Y, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: Characteristics and risk factors. Gut 2008;57:828-835.
324. Shin SH, Chung YH, Suh DD, Shin JW, Jang MK, Ryu SH, et al. Characteristic clinical features of hepatocellular carcinoma associated with Budd-Chiari syndrome: Evidence of different carcinogenic process from hepatitis B virus-associated hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2004;16:319-324.
325. Moucari R, Plessier A, Rautou PE, Consigny Y, Denninger MH, Cazals-Hatem D, et al. Hepatocellular carcinoma in Budd-Chiari syndrome: characteristics and risk factors [Abstract]. HEPATOLOGY 2006;44:461A.
326. Boudhina T, Ghram N, Ben Becher S, Lakhoua R, Ayachi R, Hammou-Jeddi A, et al. Budd-Chiari syndrome in children. Apropos of 7 cases. [in French] Arch Fr Pediatr 1991;48:243-248.
327. Gentil-Kocher S, Bernard O, Brunelle F, Hadchouel M, Maillard JN, Valayer J, et al. Budd-Chiari syndrome in children: Report of 22 cases.
328. Odell JA, Rode H, Millar AJ, Hoffman HD. Surgical repair in children with the Budd-Chiari syndrome. J Thorac Cardiovasc Surg 1995;110: 916-923.
329. Murad SD, Valla DC, de Groen PC, Zeitoun G, Haagsma EB, Kuipers EJ, et al. Pathogenesis and treatment of Budd-Chiari syndrome combined with portal vein thrombosis. Am J Gastroenterol 2006;101:83-90.
330. Gallego C, Velasco M, Marcuello P, Tejedor D, De Campo L, Friera A. Congenital and acquired anomalies of the portal venous system. Radiographics 2002;22:141-159.
331. Buscarini E, Plauchu H, Garcia-Tsao G, White RI Jr, Sabba C, Miller F, et al. Liver involvement in hereditary hemorrhagic telangiectasia: consensus recommendations. Liver Int 2006;26:1040-1046.
332. Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, Kjeldsen AD, et al. Diagnostic criteria for hereditary hemorrhagic telangiectasia (Rendu-Osler-Weber syndrome). Am J Med Genet 2000;91:65-66.
333. De Gaetano AM, Gui B, Macis G, Manfredi R, Di Stasi C. Congenital absence of the portal vein associated with focal nodular hyperplasia in the liver in an adult woman: Imaging and review of the literature. Abdom Imaging 2004;29:455-459.
334. Kim T, Murakami T, Sugihara E, Hori M, Wakasa K, Nakamura H. Hepatic nodular lesions associated with abnormal development of the portal vein. AJR Am J Roentgenol 2004;183:1333-1338.
335. Wanless IR, Lentz JS, Roberts EA. Partial nodular transformation of liver in an adult with persistent ductus venosus. Review with hypothesis on pathogenesis. Arch Pathol Lab Med 1985;109:427-432.
336. Grazioli L, Alberti D, Olivetti L, Rigamonti W, Codazzi F, Matricardi L, et al. Congenital absence of portal vein with nodular regenerative hyperplasia of the liver. Eur Radiol 2000;10:820-825.
337. Buscarini E, Danesino C, Plauchu H, de Fazio C, Olivieri C, Brambilla G, et al. High prevalence of hepatic focal nodular hyperplasia in subjects with hereditary hemorrhagic telangiectasia. Ultrasound Med Biol 2004; 30:1089-1097.
338. Garcia-Tsao G, Korzenik JR, Young L, Henderson KJ, Byrd R, Pollak JS, et al. Liver disease in patients with hereditary hemorrhagic telangiectasia. N Engl J Med 2000;343:931-936.
339. Wanless IR, Gryfe A. Nodular transformation of the liver in hereditary hemorrhagic telangiectasia. Arch Pathol Lab Med 1986;110:331-335.
340. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, et al. Mutations in the activin receptor-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nat Genet 1996;13:189-195.
341. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-beta binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nat Genet 1994;8:345-351.
342. Siddiki H, Doherty MG, Fletcher JG, Stanson AW, Vrtiska TJ, Hough DM, et al. Abdominal findings in hereditary hemorrhagic telangiectasia: pictorial essay on 2D and 3D findings with isotropic multiphase CT. Radiographics 2008;28:171-184.
343. Ianora AA, Memeo M, Sabba C, Cirulli A, Rotondo A, Angelelli G. Hereditary hemorrhagic telangiectasia: Multi-detector row helical CT assessment of hepatic involvement. Radiology 2004;230:250-259.
344. Buonamico P, Suppressa P, Lenato GM, Pasculli G, D'Ovidio F, Memeo M, et al. Liver involvement in a large cohort of patients with hereditary hemorrhagic telangiectasia: Echo-color-Doppler vs multislice computed tomography study. J Hepatol 2008;48:811-812.
345. Garcia-Tsao G. Liver involvement in hereditary hemorrhagic telangiectasia (HHT). J Hepatol 2007;46:499-507.
346. Brakensiek K, Frye-Boukhriss H, Malzer M, Abramowicz M, Bahr MJ, von Beckerath N, et al. Detection of a significant association between mutations in the ACVRL1 gene and hepatic involvement in German patients with hereditary haemorrhagic telangiectasia. Clin Genet 2008; 74:171-177.
347. Lesca G, Olivieri C, Burnichon N, Pagella F, Carette MF, Gilbert-Dussardier B, et al. Genotype-phenotype correlations in hereditary hemorrhagic telangiectasia: Data from the French-Italian HHT network. Genet Med 2007;9:914-922.
348. Sabba C, Pasculli G, Lenato GM, Suppressa P, Lastella P, Memeo M, et al. Hereditary hemorrhagic telangiectasia: Clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost 2007;5:1149-1157.
349. Bayrak-Toydemir P, McDonald J, Markewitz B, Lewin S, Miller F, Chou LS, et al. Genotype-phenotype correlation in hereditary hemorrhagic telangiectasia: Mutations and manifestations. Am J Med Genet 2006; 140:463-470.
350. Letteboer TG, Mager HJ, Snijder RJ, Koeleman BP, Lindhout D, Ploos van Amstel HK, et al. Genotype - phenotype relationship in hereditary hemorrhagic telangiectasia. J Med Genet 2006;43:371-377.
351. Blewitt RW, Brown CM, Wyatt JI. The pathology of acute hepatic disintegration in hereditary haemorrhagic telangiectasia. Histopathology 2003;42:265-269.
352. Caselitz M, Bahr MJ, Bleck JS, Chavan A, Manns MP, Wagner S, et al. Sonographic criteria for the diagnosis of hepatic involvement in hereditary hemorrhagic telangiectasia (HHT). HEPATOLOGY 2003;37:1139-1146.
353. Wu JS, Saluja S, Garcia-Tsao G, Chong A, Henderson KJ, White RI. Liver involvement in hereditary hemorrhagic telangiectasia: CT and clinical findings do not correlate in symptomatic patients. AJR Am J Roentgenol 2006;187:W399-W405.
354. Khalid SK, Garcia-Tsao G. Hepatic vascular malformations in hereditary hemorrhagic telangiectasia. Semin Liver Dis 2008;28:247-258.
355. Runyon BA. Management of adult patients with ascites due to cirrhosis. HEPATOLOGY 2004;39:841-856.
356. Lerut J, Orlando G, Adam R, Sabba C, Pfitzmann R, Klempnauer J, et al. Liver transplantation for hereditary hemorrhagic telangiectasia: Report of the European Liver Transplant Registry. Ann Surg 2006;244:854-864.
357. Garcia-Tsao G, Gish RG, Punch J. MELD exception for hereditary hemorrhagic telangiectasia. Liver Transpl 2006;12(Suppl 3):S108-S109.
358. Boillot O, Bianco F, Viale JP, Mion F, Mechet I, Gille D, et al. Liver transplantation resolves the hyperdynamic circulation in hereditary hemorrhagic telangiectasia with hepatic involvement. Gastroenterology 1999; 116:187-192.
359. Dominguez IB, Annet L, Waignein F, Sempoux C, Geubel A. Extensive ischemic liver necrosis complicating hereditary hemorrhagic telangiectasia: A rare indication for liver transplantation. Liver Int 2005;25:677-679.
360. Hillert C, Broering DC, Gundlach M, Knoefel WT, Izbicki JR, Rogiers X. Hepatic involvement in hereditary hemorrhagic telangiectasia: An unusual indication for liver transplantation. Liver Transpl 2001;7:266-268.
361. Flieger D, Hainke S, Fischbach W. Dramatic improvement in hereditary hemorrhagic telangiectasia after treatment with the vascular endothelial growth factor (VEGF) antagonist bevacizumab. Ann Hematol 2006;85: 631-632.
362. Mitchell A, Adams LA, MacQuillan G, Tibballs J, vanden Driesen R, Delriviere L. Bevacizumab reverses need for liver transplantation in hereditary hemorrhagic telangiectasia. Liver Transpl 2008;14:210-213.
363. Gallego C, Miralles M, Marin C, Muyor P, Gonzalez G, Garcia-Hidalgo E. Congenital hepatic shunts. Radiographics 2004;24:755-772.
364. Morgan G, Superina R. Congenital absence of the portal vein: Two cases and a proposed classification system for portasystemic vascular anomalies. J Pediatr Surg 1994;29:1239-1241.
365. Murray CP, Yoo SJ, Babyn PS. Congenital extrahepatic portosystemic shunts. Pediatr Radiol 2003;33:614-620.
366. Yoshimoto Y, Shimizu R, Saeki T, Harada T, Sugio Y, Nomura S, et al. Patent ductus venosus in children: A case report and review of the literature. J Pediatr Surg 2004;39:E1-E5.
367. Ortiz M, Cordoba J, Alonso J, Rovira A, Quiroga S, Jacas C, et al. Oral glutamine challenge and magnetic resonance spectroscopy in three patients with congenital portosystemic shunts. J Hepatol 2004;40: 552-557.
368. Wojcicki M, Haagsma EB, Gouw AS, Slooff MJ, Porte RJ. Orthotopic liver transplantation for portosystemic encephalopathy in an adult with congenital absence of the portal vein. Liver Transpl 2004;10:1203-1207.